Averion Provides Update on Core Offerings.

Clinical Research Organization Offers Expert Regulatory and Validation Services Including Clinical Staffing

BOSTON -- Averion International Corp. (OTCBB:AVRO) today provided an update on integration activities that further enhance its full-service clinical research offerings and align its regulatory and validation consulting to improve its competitive position. Clinical staffing services will continue to be offered.

Averion was formed through the combination of publicly traded IT&E International, and privately held Millennix Inc. and Averion Inc. The combined company formally changed its name to Averion International Corp. in September 2006. Previously operating as separately branded divisions of Averion, IT&E International and Millennix Inc. now operate and offer their services under the Averion name.

Averion's regulatory and validation consulting services have been offered for more than a decade through the former IT&E International. These services, which are provided both on site and on a consulting basis, include the placement of skilled professionals for regulatory planning, operations development, computer system validation, and ensuring U.S. Food and Drug Administration (FDA) compliance and validation of pharmaceutical laboratories, manufacturing facilities and processes.

Averion's clinical staffing services include placement of seasoned clinical staff in the areas of biostatistics, data management, medical affairs, pharmacovigilance, project management, site monitoring, and regulatory affairs.

Averion continues to offer comprehensive clinical research services, including Phase I-IV clinical trials management, patient registries, compassionate access and post-marketing safety studies. Our therapeutic focus includes oncology, medical devices, nephrology, dermatology, and critical care.

"We are building a quality image for our full-service CRO and staffing offering under the Averion name to reflect the cohesiveness of our offering and improve our competitive position," said Philip T. Lavin, PhD, Averion Chief Executive Officer. "Our mission is to create value for our clients by maximizing the chances for product success, agency approval, and health care utilization through this vertical integration. Averion International Corp. stands ready to work side by side with our clients to help them speed products through the regulatory process."

About Averion International Corp.

Averion International Corp. is a full service clinical research organization (CRO) that provides clinical research and staffing services to the pharmaceutical, biotechnology and medical device/diagnostic industries. The Company has a therapeutic focus in oncology, dermatology, nephrology and medical devices. Averion's clinical research core competencies are in FDA and product registration support, site selection, project management, medical and site monitoring, data management, biometrics, pharmacovigilance, medical writing, and full clinical trial management services throughout the clinical trials lifecycle. The Company has supported FDA approvals for products in many therapeutic areas including: oncology, medical devices, dermatology, nephrology and cardiology. The Company also provides staffing services to help solve many regulatory and validation problems faced by clients throughout the product development lifecycle.

Averion is headquartered in Southborough, Mass. and has additional U.S. office locations in New York, Philadelphia and San Diego, as well as European offices in Germany, United Kingdom, Austria and Poland. (www.averionintl.com)

Forward-Looking Statement 

Included in this press release are "forward-looking statements." Statements in this press release that are forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates" and similar expressions. Although the Company *believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission, including its most recent 10-KSB. The Company is not under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.